Table 1.
Tumor histology: subtype and stage among BRCA mutation carriers and non-carriers
| Tumor type | Total sample (N = 232) |
Invasive cancers (n = 209) |
Borderline tumors (n = 23) |
BRCA1+ (n = 20) |
BRCA2+ (n = 12) |
Total BRCA+ (N = 32) |
Total non-carriers (N = 200) |
|---|---|---|---|---|---|---|---|
| Serous | 135 (58.2%) | 121 (57.9%) | 14 (60.9%) | 14 (70%) | 6 (50%) | 20 (63%) | 115 (57.5%) |
| Endometrioid | 30 (12.9%) | 29 (13.9%) | 1 (4.3%) | 1 (5%) | 2 (16.8%) | 3 (9%) | 27 (13.5%) |
| Transitional | 3 (1.3%) | 3 (14.4%) | 0 (0%) | 1 (5%) | 0 (0%) | 1 (3%) | 2 (0.1%) |
| Mucinous | 19 (8.2%) | 13 (6.2%) | 6 (26.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 19 (9.5%) |
| Mixed | 20 (8.6%) | 18 (8.6%) | 2 (8.7%) | 4 (20%) | 1 (8.3%) | 5 (16%) | 15 (7.5%) |
| Peritoneal | 6 (2.6%) | 6 (2.9%) | 0 (0%) | 0 (0%) | 1 (8.3%) | 1 (3%) | 5 (2.5%) |
| Brenner | 3 (1.3%) | 3 (1.4%) | 0 (0%) | 0 (0%) | 1 (8.3%) | 1 (3%) | 1 (1%) |
| Clear cell | 9 (3.9%) | 9 (4.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (4.5%) |
| Unknown | 7 (3.0%) | 7 (3.3%) | 0 (0%) | 0 (0%) | 1 (8.3%) | 1 (3%) | 6 (3%) |
| Stage | |||||||
| I | 47 (20.3%) | 28 (13.4%) | 19 (82.6%) | 1 (5%) | 4 (33.4%) | 5 (15.6%) | 42 (21.0%) |
| II | 20 (8.6%) | 20 (9.6%) | 0 (0%) | 3 (15%) | 1 (8.3%) | 4 (12.5%) | 16 (8.0%) |
| III | 136 (58.6%) | 132 (63.15%) | 4 (17.4%) | 13 (65%) | 6 (50%) | 19 (59.4%) | 117 (58.5%) |
| IV | 28 (12.1%) | 28 (13.4%) | 0 (0%) | 3 (15%) | 1 (8.3%) | 4 (12.5%) | 24 (12.0%) |
| Unknown | 1 (0.4%) | 1 (0.45%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.5%) |